Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting
The goal of this clinical research study is to see if pulmonary rehabilitation can improve patients' lung function, which would increase their chances of becoming eligible for surgery. The health of pulmonary rehabilitation participants after surgery will also be examined.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 16, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Other: Questionnaire; Behavioral: Pulmonary Rehabilitation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Patients with anatomically resectable lung tumors who are deemed surgically inoperable based on preoperative pulmonary function testing FEV1 \< 80% pred; DLCO \< 80% pred; FEV1ppo \< 40% pred; DLCO ppo \< 40% pred AND VO2 peak \< 60% predicted or \< 15 ml/kg/min. 2. Patients deemed surgically inoperable based on poor performance status (ECOG score 2-3) 3. Any non-pulmonary co-morbidity must be stable according to institutional guidelines.
1. Previously reported severe pulmonary hypertension (pulmonary artery systolic pressure \> 60 as determined by echocardiogram), refractory cor pulmonale (as manifested by right ventricular dilatation or dysfunction by echocardiogram) 2. Previously reported exercise-induced syncope, angina, palpitation, arrhythmia, hypotension (drop of 20% of systolic/diastolic from baseline) 3. History of severe congestive heart failure (NYHA class 3 and 4) refractory to medical management, (LVEF \< 40% by echocardiogram). 4. Bone metastasis 5. Active psychiatric illness that could interfere with treatment.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Texas MD Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 16, 2026. Always confirm current availability with the study team.